CreativeOne Wealth LLC Has $442,000 Stock Position in Novo Nordisk A/S $NVO

Key Points

• CreativeOne Wealth LLC reduced its holdings in Novo Nordisk A/S by 68.3%, owning 6,359 shares worth approximately $442,000 after selling 13,685 shares.
• Novo Nordisk reported $0.97 earnings per share for the last quarter, surpassing estimates of $0.93, with a net margin of 35.60% and revenue of $11.69 billion.
• The company declared a semi-annual dividend of $0.4119 per share, translating to a significant dividend yield of 240.0%.

CreativeOne Wealth LLC lessened its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 68.3% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 6,359 shares of the company's stock after selling 13,685 shares during the quarter. CreativeOne Wealth LLC's holdings in Novo Nordisk A/S were worth $442,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Copeland Capital Management LLC increased its stake in Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after buying an additional 255 shares during the period. North Capital Inc. acquired a new position in Novo Nordisk A/S in the 1st quarter valued at approximately $27,000. Park Square Financial Group LLC acquired a new position in Novo Nordisk A/S in the 4th quarter valued at approximately $29,000. Stone House Investment Management LLC acquired a new position in Novo Nordisk A/S in the 1st quarter valued at approximately $30,000. Finally, Disciplina Capital Management LLC increased its stake in Novo Nordisk A/S by 162.3% in the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company's stock valued at $33,000 after buying an additional 297 shares during the period. Institutional investors and hedge funds own 11.54% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on NVO shares. Zacks Research lowered shares of Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a research note on Wednesday, August 20th. Dbs Bank upgraded shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research note on Friday, August 22nd. BNP Paribas upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a research note on Wednesday, August 13th. Hsbc Global Res lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 31st. Finally, Barclays reiterated an "equal weight" rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. Three investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Novo Nordisk A/S has an average rating of "Hold" and a consensus price target of $81.00.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock traded down $0.09 during mid-day trading on Tuesday, reaching $56.37. The company had a trading volume of 11,609,027 shares, compared to its average volume of 11,758,394. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 52 week low of $45.05 and a 52 week high of $138.62. The company has a 50 day moving average of $60.46 and a 200-day moving average of $68.12. The firm has a market cap of $251.69 billion, a price-to-earnings ratio of 15.49, a PEG ratio of 1.96 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The firm had revenue of $11.69 billion during the quarter, compared to the consensus estimate of $77.51 billion. On average, sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were issued a dividend of $0.4119 per share. This represents a dividend yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 22.53%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.